NICHD P1081: Improved Virologic Suppression at Delivery With RAL- vs EFV-Based ART in Pregnant Women With HIV Infection

March 4-7, 2019; Seattle, Washington
First large randomized study of raltegravir vs efavirenz in pregnant women finds improved virologic suppression at delivery in women receiving raltegravir, particularly when initiating ART after 28 weeks of gestation.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: March 7, 2019

Acknowledgements

Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Related Content

Expert-authored CCO slides on the impact of HIV infection on COVID-19 risk and disease severity and the impact of COVID-19 on access to HIV care

W. David Hardy, MD
Program Director
Monica Gandhi, MD, MPH
Released: September 25, 2020

Expert-authored CCO slides on current and future HIV prevention strategies, including FTC/TDF and FTC/TAF PrEP and long-acting injectable PrEP

W. David Hardy, MD
Program Director
Gregory Huhn, MD, MPHTM
Released: September 25, 2020

Short video log from Dr. Jonathan Appelbaum on managing ART and reducing polypharmacy in an older woman with HIV who presents with frailty and multiple other comorbidities

Jonathan Appelbaum, MD, FACP, AAHIVS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2020 Expired: September 23, 2021

Download free expert-authored slides reviewing a patient case and the relevant data on polypharmacy and drug-drug interactions in older patients with HIV

Jonathan Appelbaum, MD, FACP, AAHIVS Released: September 24, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue